ArticleJournal of asthma and allergy2025
Efficacy of Benralizumab in Reducing FeNO in Severe Eosinophilic Asthma: The Role of CRSwNP.
Article in Journal of asthma and allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Benralizumab, targeting the IL-5 receptor, reduces exacerbations and improves lung function in severe eosinophilic asthma. Data on its effect on fractional exhaled nitric oxide (FeNO), particularly in patients with and without chronic rhinosinusitis with nasal polyps (CRSwNP), are limited. Objective: This study evaluates benralizumab's impact on FeNO levels in severe eosinophilic asthma, focusing on the presence of CRSwNP. Methods: We retrospectively analyzed 43 patients with severe eosinophilic asthma treated with benralizumab. Patients were divided into CRSwNP (N=13) and non-CRSwNP (N=30) groups. Baseline characteristics, FeNO levels, FEV1, FVC, ACT scores, exacerbations, and oral corticosteroid (OCS) use were recorded at baseline, 3, 6, and 12 months. Results: At baseline, FeNO levels were higher in CRSwNP patients than in non-CRSwNP (82.80 ppb vs 41.86 ppb, P = 0.019). Over 12 months, FeNO significantly decreased in CRSwNP patients (-29.69 ppb, P = 0.036) and remained stable in non-CRSwNP patients (+3.55 ppb, P = 0.036). Significant improvements were observed in FEV1 (0.59L vs 0.38L, P = 0.017) and ACT scores (6.46 vs 4.01, P < 0.001) in CRSwNP patients. Both groups showed a notable reduction in exacerbations, which was more pronounced in CRSwNP patients (-3.12 vs -3.60, P < 0.001). OCS withdrawal was achieved in 53.8% of CRSwNP patients and 43.3% of non-CRSwNP patients. Conclusion: Benralizumab reduces FeNO levels and improves clinical outcomes in severe eosinophilic asthma, especially in patients with CRSwNP. Monitoring FeNO levels provides additional insights into treatment response, highlighting its potential role as a marker in specific patient subgroups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.